The Latest Breaking News from Evusheld

The Food and Drug Administration has withdrawn its provisional support for the use of Evusheld, a medication that was once a valuable tool for preventing patients with weakened immune systems from becoming severely ill with COVID-19.

In February 2022, the UK government abandoned its remaining pandemic restrictions in favour of “living with COVID”. This approach relies largely on vaccines protecting people from severe disease.

Pharmaceutical CEO says it’s ‘sad’ that UK has failed to order Evusheld for the immunosuppressed

AstraZeneca Plc's (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete the delivery by half year 2022. Core EPS came in at $1.89,…

Here's a roundup of top developments in the biotech space over the last 24 hours.

AstraZeneca plc (NASDAQ:AZN) shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442. The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo.  There were no…

The Centre for Covid-19 Situation Administration (CCSA) has approved a plan to procure a long-acting coronavirus antibody cocktail for people with poor immune systems who cannot be vaccinated.

Infectious disease physician Patrick Jackson of the University of Virginia explains how it works, who’s eligible and why some patients are having difficulties accessing it.

The U.S. Food and Drug Administration granted emergency use authorization to AstraZeneca’s COVID-19 antibody drug Evusheld on Dec. 8, 2021. Infectious disease physician Patrick Jackson of the University of Virginia explains how it works, who’s eligible and why some patients are having difficulties accessing it.